IDEXX Laboratories/$IDXX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About IDEXX Laboratories
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets close to 35% of its revenue from outside the United States.
Ticker
$IDXX
Sector
Primary listing
Industry
Health Care Equipment & Supplies
Headquarters
Employees
11,000
ISIN
US45168D1046
Website
IDXX Metrics
BasicAdvanced
$42B
48.07
$10.82
1.52
-
Price and volume
Market cap
$42B
Beta
1.52
52-week high
$530.73
52-week low
$356.14
Average daily volume
534K
Financial strength
Current ratio
1.16
Quick ratio
0.609
Long term debt to equity
37.762
Total debt to equity
64.932
Interest coverage (TTM)
34.12%
Profitability
EBITDA (TTM)
1,341.508
Gross margin (TTM)
61.28%
Net profit margin (TTM)
22.76%
Operating margin (TTM)
30.71%
Effective tax rate (TTM)
20.41%
Revenue per employee (TTM)
$360,000
Management effectiveness
Return on assets (TTM)
22.98%
Return on equity (TTM)
59.33%
Valuation
Price to earnings (TTM)
48.067
Price to revenue (TTM)
10.845
Price to book
28.99
Price to tangible book (TTM)
44.98
Price to free cash flow (TTM)
50.901
Free cash flow yield (TTM)
1.96%
Free cash flow per share (TTM)
1,021.31%
Growth
Revenue change (TTM)
5.56%
Earnings per share change (TTM)
4.80%
3-year revenue growth (CAGR)
6.29%
10-year revenue growth (CAGR)
10.06%
3-year earnings per share growth (CAGR)
8.29%
10-year earnings per share growth (CAGR)
19.42%
What the Analysts think about IDXX
Analyst ratings (Buy, Hold, Sell) for IDEXX Laboratories stock.
Bulls say / Bears say
IDEXX Laboratories reported strong fourth-quarter earnings for 2024, with revenue reaching $954 million, surpassing the expected $935 million, driven by robust demand for its animal testing products and higher prices. (Monexa)
The company's Companion Animal Group (CAG) segment continues to be a key growth driver, benefiting from the increasing trend of pet humanization, with pet owners willing to spend more on advanced diagnostics and healthcare for their animals. (Monexa)
IDEXX Laboratories has demonstrated strong financial health, with net income growing at a CAGR of 15.5% since 2013, and free cash flow increasing at a CAGR of 13.4% in the same period, showcasing the company's operational efficiency and ability to generate cash from its operations. (Nasdaq)
IDEXX Laboratories has lowered its annual revenue forecast for the third time due to a decrease in veterinary clinic visits amid inflationary pressures and staffing challenges, now anticipating full-year revenue between $3.87 billion and $3.89 billion, down $38 million from previous predictions. (Reuters)
The company has a net debt of around $1 billion, which may raise concerns among investors about its financial leverage and potential risks associated with debt servicing. (Nasdaq)
IDEXX Laboratories' operating margin has seen a slight decline, with the fourth quarter of 2023 reporting a margin of 27.2%, down from 27.3% in the same period the previous year, indicating potential challenges in maintaining profitability. (Business Wire)
Data summarised monthly by Lightyear AI. Last updated on 7 Jun 2025.
IDXX Financial Performance
Revenues and expenses
IDXX Earnings Performance
Company profitability
IDXX News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for IDEXX Laboratories stock?
IDEXX Laboratories (IDXX) has a market cap of $42B as of June 20, 2025.
What is the P/E ratio for IDEXX Laboratories stock?
The price to earnings (P/E) ratio for IDEXX Laboratories (IDXX) stock is 48.07 as of June 20, 2025.
Does IDEXX Laboratories stock pay dividends?
No, IDEXX Laboratories (IDXX) stock does not pay dividends to its shareholders as of June 20, 2025.
When is the next IDEXX Laboratories dividend payment date?
IDEXX Laboratories (IDXX) stock does not pay dividends to its shareholders.
What is the beta indicator for IDEXX Laboratories?
IDEXX Laboratories (IDXX) has a beta rating of 1.52. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.